201 related articles for article (PubMed ID: 18162776)
1. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors.
Atkins KA; Arronte N; Darus CJ; Rice LW
Am J Surg Pathol; 2008 Jan; 32(1):98-102. PubMed ID: 18162776
[TBL] [Abstract][Full Text] [Related]
2. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
4. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
[TBL] [Abstract][Full Text] [Related]
5. Differential Immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants.
Gannon BR; Manduch M; Childs TJ
Int J Gynecol Pathol; 2008 Jan; 27(1):68-73. PubMed ID: 18156978
[TBL] [Abstract][Full Text] [Related]
6. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
[TBL] [Abstract][Full Text] [Related]
7. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of von Willebrand factor, CD34, CD31, and vascular endothelial growth factor expression in women with uterine leiomyosarcomas.
Poncelet C; Fauvet R; Feldmann G; Walker F; Madelenat P; Darai E
J Surg Oncol; 2004 May; 86(2):84-90. PubMed ID: 15112250
[TBL] [Abstract][Full Text] [Related]
9. Expression of the O-linked N-acetylglucosamine containing epitope H in normal myometrium and uterine smooth muscle cell tumors.
Sgantzos MN; Galani V; Arvanitis LD; Charchanti A; Psathas P; Nakou M; Havaki S; Kallioras V; Marinos E; Vamvakopoulos NC; Kittas C
Pathol Res Pract; 2007; 203(1):31-7. PubMed ID: 17129677
[TBL] [Abstract][Full Text] [Related]
10. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
Mittal K; Demopoulos RI
Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
[TBL] [Abstract][Full Text] [Related]
11. Uterine leiomyoma versus leiomyosarcoma: a new attempt at differential diagnosis based on their cellular characteristics.
Watanabe K; Suzuki T
Histopathology; 2006 Apr; 48(5):563-8. PubMed ID: 16623782
[TBL] [Abstract][Full Text] [Related]
12. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
Fertil Steril; 2004 Apr; 81(4):1062-6. PubMed ID: 15066464
[TBL] [Abstract][Full Text] [Related]
13. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
14. Uterine smooth-muscle tumor of uncertain malignant potential metastasizing to the humerus as a high-grade leiomyosarcoma.
Shapiro A; Ferenczy A; Turcotte R; Bruchim I; Gotlieb WH
Gynecol Oncol; 2004 Sep; 94(3):818-20. PubMed ID: 15350379
[TBL] [Abstract][Full Text] [Related]
15. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
Leitao MM; Soslow RA; Nonaka D; Olshen AB; Aghajanian C; Sabbatini P; Dupont J; Hensley M; Sonoda Y; Barakat RR; Anderson S
Cancer; 2004 Sep; 101(6):1455-62. PubMed ID: 15316901
[TBL] [Abstract][Full Text] [Related]
16. Reduced expression of calponin h1 in leiomyosarcoma of the uterus.
Horiuchi A; Nikaido T; Ito K; Zhai Y; Orii A; Taniguchi S; Toki T; Fujii S
Lab Invest; 1998 Jul; 78(7):839-46. PubMed ID: 9690561
[TBL] [Abstract][Full Text] [Related]
17. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases.
Bell SW; Kempson RL; Hendrickson MR
Am J Surg Pathol; 1994 Jun; 18(6):535-58. PubMed ID: 8179071
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior.
Giuntoli RL; Gostout BS; DiMarco CS; Metzinger DS; Keeney GL
J Reprod Med; 2007 Nov; 52(11):1001-10. PubMed ID: 18161397
[TBL] [Abstract][Full Text] [Related]
19. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma.
Leiser AL; Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi DS; Soslow RA
Gynecol Oncol; 2006 Apr; 101(1):86-91. PubMed ID: 16289259
[TBL] [Abstract][Full Text] [Related]
20. Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma.
Zhang Q; Ubago J; Li L; Guo H; Liu Y; Qiang W; Kim JJ; Kong B; Wei JJ
Cancer; 2014 Oct; 120(20):3165-77. PubMed ID: 24986214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]